Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 , /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ: TNDM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Tandem and certain of its officers and/or directors have engaged ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2025 results after the financial markets close on Thursday, November 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diab. ...

LOS ANGELES, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TANDEM DIABETES CARE, INC. (TNDM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On August 7, 2025, Ta ...

LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Tandem Diabetes Care, Inc. (“Tandem” or the “Company”) (NASDAQ: TNDM) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON TANDEM DIABETES CARE, INC. (TNDM), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.   What Is The Investigation About? On August 7, 2025, Tandem disclosed that a m ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information [1] Group 1: Company Information - Tandem Diabetes Care issued a press release on August 7, 2025, regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3] - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3] Group 2: Legal Actions - Rosen Law Firm is preparing a class action lawsuit to seek recovery of investor losses for those who purchased Tandem Diabetes Care securities, with no out-of-pocket fees for participants through a contingency fee arrangement [2] - Investors interested in joining the class action can submit their information through the Rosen Law Firm's website or contact them directly [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4]

Group 1 - The article discusses an opportunity for investors in Tandem Diabetes Care, Inc. to participate in a fraud investigation led by the Schall Law Firm [1] - The investigation is focused on potential fraudulent activities that may have impacted the company's stock performance [1] - Investors are encouraged to join the investigation to seek accountability and potential recovery of losses [1]

Company Overview - Tandem Diabetes Care, Inc. (NASDAQ:TNDM) specializes in developing insulin delivery systems, digital health tools, infusion sets, cartridges, and platforms aimed at supporting diabetes management [2]. Investment Insights - The stock has been highlighted by Jim Cramer, who noted the personal connection of users to the company's products, suggesting a speculative investment opportunity for younger investors despite ongoing financial losses [1]. - Cramer expressed a willingness to support the company due to its potential, particularly for younger individuals who have time to recover from investment mistakes [1]. Market Comparison - While Tandem Diabetes Care shows potential, there are other AI stocks that may offer greater upside potential and lower downside risk, indicating a competitive investment landscape [3].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a press release from Tandem Diabetes Care on August 7, 2025, regarding a voluntary medical device correction for select t:slim X2 insulin pumps, which indicated a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Class Action Information - Shareholders who purchased Tandem Diabetes Care securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Group 1: Phillips 66 - Phillips 66 announced a definitive agreement to acquire the remaining 50% ownership interest in WRB Refining LP from subsidiaries of Cenovus Energy [1] - Shares of Phillips 66 fell 0.7% to settle at $131.42 on Wednesday [5] Group 2: Tandem Diabetes Care - Oppenheimer analyst maintained Tandem Diabetes Care with an Outperform rating and lowered the price target from $44 to $22 [2] - Tandem Diabetes Care shares fell 1.5% to settle at $12.37 on Wednesday [5] - Cramer described Tandem Diabetes Care as a "speculative stock for younger people" [1] Group 3: Cintas - Cramer recommended buying Cintas stock and suggested waiting for the quarter results [2] - Cintas announced it will release fiscal year 2026 first-quarter results on September 24 [2] - Cintas shares fell 0.3% to close at $201.40 [5] Group 4: Intuitive Surgical - Intuitive Surgical reported second-quarter revenue of $2.44 billion, beating analyst estimates of $2.35 billion [3] - The company reported second-quarter adjusted earnings of $2.19 per share, exceeding analyst estimates of $1.93 per share [3] - Shares of Intuitive Surgical fell 3.8% to close at $449.98 [5]

Group 1: Phillips 66 - Phillips 66 announced a definitive agreement to acquire the remaining 50% ownership interest in WRB Refining LP from subsidiaries of Cenovus Energy [1] Group 2: Tandem Diabetes Care - Oppenheimer analyst maintained an Outperform rating for Tandem Diabetes Care but lowered the price target from $44 to $22 [2] - Tandem Diabetes Care shares fell 1.5% to settle at $12.37 [5] Group 3: Cintas - Cintas is recommended for purchase, with a suggestion to buy more if the upcoming quarter's results are disappointing [2] - Cintas shares fell 0.3% to close at $201.40 [5] Group 4: Intuitive Surgical - Intuitive Surgical reported second-quarter revenue of $2.44 billion, exceeding analyst estimates of $2.35 billion [3] - The company reported second-quarter adjusted earnings of $2.19 per share, beating analyst estimates of $1.93 per share [3] - Intuitive Surgical shares fell 3.8% to close at $449.98 [5]